Summary
Vinorelbine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Lung Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Lung Cancer. ClinicalTrials.gov lists 8 registered trials linking Vinorelbine to Lung Cancer: 1 is active or not yet recruiting; 5 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT02352948). It plans or enrolled 597 participants. Registration activity spans 1999 to 2019. The literature layer holds 16 publications for this pair: 5 Cochrane reviews, 2 meta-analyses, 4 systematic reviews and 5 clinical trial publications. Publication years run from 2018 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Lung Cancer ranks 465 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for stage I-II with surgery.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 74.0 (trials 24.0, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 1 active / not yet recruiting, 5 completed, 2 other |
| Linked publications | 16 (5 Cochrane reviews, 5 clinical trial publications, 4 systematic reviews, 2 meta-analyses) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | BRCA1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT03456076 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer 2018 | active, not recruiting | Phase 3 | 257 |
| NCT02352948 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer 2015 | completed | Phase 3 | 597 |
| NCT03891173 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma 2019 | terminated | Phase 2 | 9 |
| NCT00705549 | Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer 2008 | terminated | Phase 2 | 88 |
| NCT00001944 | Vinorelbine and XR9576 to Treat Cancer 1999 | completed | Phase 1 | 30 |
| NCT02603003 | the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs 2015 | completed | Phase 1 | 218 |
| NCT00522886 | Phase I Cetuximab and Concurrent Radio-chemotherapy 2007 | completed | Phase 1 | 24 |
| NCT00312819 | Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer 2006 | completed | PHASE2, PHASE3 | 60 |
Published literature
- Clinical trial publication Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysisEberhardt WEE, Schulte C, Pöttgen C et al. · European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41702246
- Clinical trial publication First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulationHan B, Peters S, Le AT et al. · Chinese medical journal · 2026 · PMID 41424028
- Cochrane review Metronomic chemotherapy combined with immunotherapy in solid tumor: a systematic reviewLi S, Li Z, Liu X et al. · Translational cancer research · 2026 · PMID 42180940
- Clinical trial publication Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS StudyPeters S, Schulz C, Reck M et al. · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025 · PMID 40706710
- Clinical trial publication Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 TrialSchytte T, Knap MM, Kristiansen C et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · PMID 40249893
- Clinical trial publication Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled TrialFriis RB, Pappot H, Hjollund NH et al. · JCO oncology practice · 2025 · PMID 39657078
- Cochrane review A meta-analysis of recombinant human endostatin combined with NP regimen for treating non-small cell lung cancerGao C, Gao C, Yuan Q · Medicine · 2024 · PMID 38788043
- Cochrane review Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analysesXu K, Lu W, Yu A et al. · BMC cancer · 2024 · PMID 38632512
- Cochrane review Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancerYang QY, Zhu L, Liu HX et al. · Frontiers in pharmacology · 2022 · PMID 36105225
- Cochrane review A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancerZheng Q, Min S, Zhou Y · BMC cancer · 2022 · PMID 35725420
- Meta-analysis Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysisPang LL, Gan JD, Huang YH et al. · BMJ open · 2022 · PMID 35697451
- Meta-analysis Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant dataTaniguchi Y, Okamoto H, Shimokawa T et al. · BMC pulmonary medicine · 2022 · PMID 35000608
- Systematic review Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysisGriesinger F, Korol EE, Kayaniyil S et al. · Lung cancer (Amsterdam, Netherlands) · 2019 · PMID 31446995
- Systematic review Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trialsXiao Z, Wang CQ, Feng JH et al. · Cytotherapy · 2019 · PMID 30554868
- Systematic review Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic ReviewIqbal MS, Vashisht G, McMenemin R et al. · Clinical oncology (Royal College of Radiologists (Great Britain)) · 2019 · PMID 30415784
- Systematic review Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic reviewLesueur P, Martel-Laffay I, Escande A et al. · Expert review of anticancer therapy · 2018 · PMID 30173589
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Vinorelbine approved for Lung Cancer?
Vinorelbine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Lung Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Lung Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Vinorelbine in clinical trials for Lung Cancer?
ClinicalTrials.gov lists 8 registered trials linking Vinorelbine to Lung Cancer: 1 is active or not yet recruiting; 5 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT02352948). It plans or enrolled 597 participants. Registration activity spans 1999 to 2019.
What does the evidence show for Vinorelbine in Lung Cancer?
Vinorelbine has both completed registered trials and synthesis-level publications linked to Lung Cancer. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.